Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1117 in Healthy Volunteers
NCT06828393Phase 1Recruiting
- Sponsor
- Seismic Therapeutic
- Start
- Mar 2025
- Primary completion
- Mar 2026
- Modality
- Therapeutic Enzymes, Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of S-1117 in myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), immune thrombocytopenia (ITP) and 1 more (2 arms), sponsored by Seismic Therapeutic. Primary endpoint: Number of participants with treatment-related adverse and serious adverse events at 2 months. Started Mar 2025; status: recruiting.
02
Drugs
S-1117
03
Conditions
myasthenia gravis (MG)chronic inflammatory demyelinating polyneuropathy (CIDP)immune thrombocytopenia (ITP)autoimmune diseases
Beyond the preview
Go deeper on NCT06828393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06828393.